SCHEMBL24253561

SCHEMBL24253561

Cc1ccc2cc(C(C)C(C)C)ccc2n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.55
KDM4E B2RXH2 2/20 0.52
LMNA P02545 1/20 0.52
POLB P06746 1/20 0.52
CASP6 P55212 1/20 0.52
KDM1A O60341 1/20 0.39
RAB9A P51151 5/20 0.38
NPC1 O15118 4/20 0.38
AKR1C3 P42330 1/20 0.36
AKR1C2 P52895 1/20 0.36
PIK3CD O00329 1/20 0.36
ABL1 P00519 1/20 0.36
EGFR P00533 1/20 0.36
HCK P08631 1/20 0.36
SRC P12931 1/20 0.36
KDR P35968 1/20 0.36
PIK3CA P42336 1/20 0.36
PIK3CB P42338 1/20 0.36
MTOR P42345 1/20 0.36
PIK3CG P48736 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1102403 0.85 CYP1A2 (0.59) CYP1A2KDM4ELMNAPOLBCASP6
SCHEMBL24654879 0.81 CYP1A2 (0.55) CYP1A2KDM4ELMNAPOLBCASP6
SCHEMBL31201745 0.81 CYP1A2 (0.55) CYP1A2KDM4ELMNAPOLBCASP6
SCHEMBL27684617 0.77 CYP1A2 (0.50) CYP1A2KDM4ELMNAPOLBCASP6
SCHEMBL27684616 0.77 CYP1A2 (0.50) CYP1A2KDM4ELMNAPOLBCASP6
SCHEMBL23502417 0.77 KCNH2 (0.38) CYP1A2NCK1BACE1
SCHEMBL12436949 0.75 CYP1A2 (0.52) CYP1A2KDM4ELMNAPOLBCASP6
SCHEMBL27498518 0.75 KDM4E (0.49) CYP1A2KDM4ELMNAPOLBCASP6
SCHEMBL22521436 0.73 ALDH1A1 (0.55) KDM4ELMNAPOLBRAB9ANPC1
SCHEMBL23053282 0.73 CYP1A2 (0.49) CYP1A2KDM4ELMNAPOLBCASP6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230250080-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LTD (GB) 2023-08-10 US disclosed
US-11613527-B2 Enzyme inhibitors KALVISTA PHARMACEUTICALS LIMITED (GB) 2023-03-28 US disclosed
US-20220048894-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250080-A1 ENZYME INHIBITORS SERPINB1, KLKB1, SERPINE1 CYP1A2 876/4885KDM4E 1403/4885LMNA 728/4885
US-11613527-B2 Enzyme inhibitors SERPINB1, KLKB1, SERPINE1 CYP1A2 876/4885KDM4E 1403/4885LMNA 728/4885
US-20220048894-A1 ENZYME INHIBITORS SERPINB1, KLKB1, SERPINE1 CYP1A2 876/4885KDM4E 1403/4885LMNA 728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.